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Any long-term programme for disease control that relies on one type of inter-vention has a high probability of failure 
owing to the development of treatment resist-
ance. Efforts to limit malaria by using insecti-
cides to kill female mosquitoes, which transmit 
the disease-causing Plasmodium parasite, are 
no exception: mosquito resistance to insecti-
cides is on the increase. Writing in Nature, 
Paton et al.1 report a non-insecticidal interven-
tion that stops mosquitoes from transmitting 
malaria and that might offer a way to reduce 
the reliance on insecticides alone as a means of 
malaria prevention. 
It is estimated2 that mosquito control 
using bed nets impregnated with long-lasting 
insecticides called pyrethroids, and indoor 
insecticide spraying, resulted in 1.3 billion 
fewer malaria cases and 6 million to 8 mil-
lion [Should this be 6.8 million see the 1st 
par: https://www.sciencedirect.com/science/
article/pii/S0140673618308444?via%3Dihu
b#bib2] fewer deaths between 2000 and 2015. 
However, despite these intensive efforts, a 2018 
report3 by the World Health Organization 
(WHO) states that, between 2015 and 2017, 
global efforts to reduce the burden of malaria 
stalled. 
The report highlights a funding gap that has 
resulted in a failure to achieve universal cover-
age of bed nets, where needed, and an increase 
in resistance to antimalarial drugs and insec-
ticides. The report mentions the limited data 
available on insecticide resistance, and states 
that the impact of pyrethroid resistance on 
the effectiveness of current pyrethroid-based 
interventions is poorly understood. Although 
mentioning that such increasing resistance will 
probably reduce the efficacy of current inter-
ventions, it downplays the potential impact on 
the use of pyrethroid-treated bed nets, stating 
that the nets, which have been responsible for 
approximately 68% of the estimated reduction 
in malarial transmission since 2000 (ref. 4), 
continue to be effective. Sadly, this optimism 
seems misplaced, given the evidence that the 
increased insecticide resistance is affecting the 
level of disease transmission. 
Models had already predicted5 that insecti-
cide resistance would affect malaria transmis-
sion. A type of bed net called a PBO net that 
contains pyrethroid and piperonyl butoxide, 
a compound that enhances pyrethroid’s effec-
tiveness, would be substantially more effective 
than pyrethroid-only nets5. Models of trans-
mission dynamics5 indicate that even low lev-
els of insecticide resistance would increase the 
incidence of malaria because of the effect of 
reduced mosquito mortality and lower over-
all community protection during the projected 
three-year lifespan of a bed net. It is estimated 
that switching from pyrethroid-only bed nets 
to PBO nets would prevent up to 0.5 clinical 
cases of malaria per person per year in some 
scenarios5. Trials have demonstrated that PBO 
nets used in insecticide-resistant areas are 
more effective at reducing the transmission of 
malaria than are pyrethroid-only nets6. 
Given the urgent need to expand the range 
of effective interventions, Paton et al. suggest 
a way forward for the development of next-
generation antimalarial bed nets. They tested 
whether Plasmodium falciparum, the major 
malaria-causing parasite in Africa, could be 
killed by exposing mosquitoes to the parasite-
killing drugs that are used to prevent people 
from getting malaria, and which target mito-
chondria — the parasite’s energy-generating 
organelles. 
The authors found that the antimalarial drug 
atovaquone, which inhibits the mitochondrial 
protein cytochrome b, as well as other types of 
cytochrome b inhibitor drug, could kill para-
sites in a mosquito host. Exposing mosquitoes 
for six minutes to a glass surface coated with 
low doses of the drug was enough to have an 
effect. This is within the time frame for which 
wild mosquitoes rest on bed nets. The finding 
is important because, after more than a century 
of research, and small-scale projects involving 
biological or environmental control, it is evi-
dent that non-insecticidal interventions do not 
contribute substantially to efforts to reduce 
malaria transmission.
Paton and colleagues suggest that anti-
malarial drugs could be incorporated into 
bed nets alongside insecticides (Fig. 1). Their 
modelling predicts that this would reduce 
the prevalence of malaria, with the size of the 
impact being affected by the levels of disease 
transmission, the number of people using nets 
and the degree of insecticide resistance. The 
increased effect of adding the anti malarial 
drug to insecticide-treated nets is most strik-
ing in the authors’ models when bed-net usage 
is 70–100%, underscoring the need to strive for 
high levels of net usage even if the compounds 
used to treat the nets change in the future.
Malaria cannot be sustainably controlled or 
eliminated without effective mosquito control. 
Paton and colleagues’ approach fits well with 
the WHO global plan for managing insecticide 
resistance7. This suggests that a multifaceted 
approach should be used, and progress will 
rely on efforts to reduce the cost of bringing 
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Figure 1 | A non-insecticidal treatment blocks 
malaria transmission. Transmission of the 
Plasmodium parasite to humans by mosquitoes 
causes malaria. A standard disease-prevention 
approach is the treatment of bed nets with 
insecticides that kill mosquitoes. However, 
mosquito resistance to insecticides is on the rise. 
Paton et al.1 report that exposing mosquitoes to 
surfaces treated with antimalarial drugs targeting 
the parasite kills the parasite in its host. The 
authors studied drugs that target the protein 
cytochrome b in mitochondria — the cell’s energy-
generating organelles. They report that these 
drugs block the development of ookinete-stage 
Plasmodium parasites in the mosquito midgut. 
And they suggest that bed-net treatment that 
combines both insecticides and parasite-targeting 
compounds might offer a way forward in efforts 
to develop new ways to tackle malaria. Killing the 
parasite in this way would prevent insecticide-
resistant mosquitoes from transmitting disease. 
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new drugs to market and streamlining the 
associated development, policy and imple-
mentation steps8. Although Paton and col-
leagues’ approach holds promise, substantial 
hurdles must be overcome before a product 
is generated that is recommended and uni-
versally accepted by funders, countries and 
communities for use in control programmes. 
Extensive work will be needed to optimize 
drug development, and so produce long-
lasting formulations. Moreover, assessments 
of the drug-manufacturing process should be 
undertaken, together with a drug’s resistance 
potential and the cost and public acceptability 
of the approach. 
The WHO has a system called prequalifica-
tion, in which a product for tackling a health 
problem must meet certain specifications 
before it can be placed on a list for selection 
by donor organizations. In addition, countries 
have product-recommendation systems that 
consider proposed interventions and estab-
lish the burden of proof for whether a WHO 
recommendation is warranted for use there. 
Completing these steps is a difficult and 
lengthy process. For example, the first PBO 
nets were a market-ready product bearing 
a WHO interim recommendation ten years 
before the first WHO guidance was issued 
on where and when this type of net should be 
used2. The combined developmental, regula-
tory and other processes involved can create a 
20-year hiatus before a new technology enters 
the marketplace and is used at scale. Substan-
tial effort and funding will therefore be needed 
to ensure a rapid evaluation of whether Paton 
and colleagues’ suggested approach could have 
a role in reversing the current trend of rising 
malaria transmission. ■
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